TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 CNY | -1.07% |
|
0.00% | -12.97% |
| 03-01 | Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue | MT |
| 02-29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 7.45B 1.03B 1.41B | Sales 2025 * | 8.51B 1.17B 1.61B | Capitalization | 11.09B 1.53B 2.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 706M 97.43M 133M | Net income 2025 * | 853M 118M 161M | EV / Sales 2024 * | 1.49 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
15.4
x | P/E ratio 2025 * |
13.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.5% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.07% | ||
| Current month | -5.63% | ||
| 1 month | -6.11% | ||
| 3 months | -5.14% | ||
| 6 months | -12.56% | ||
| Current year | -12.97% |
1 week
3.59
3.76
1 month
3.584.02
Current year
3.074.39
1 year
3.076.59
3 years
3.079.90
5 years
3.079.90
10 years
2.9210.93
| Managers | Title | Age | Since |
|---|---|---|---|
Dan Zheng
CEO | Chief Executive Officer | 60 | - |
Wu Jun Lan
DFI | Director of Finance/CFO | 49 | - |
Wu Sun
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Qing Yao
FOU | Founder | 59 | 96-09-22 |
Li Li
BRD | Director/Board Member | 63 | 20-11-17 |
Peng Fei Tu
BRD | Director/Board Member | 61 | 20-01-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.69 | -1.07% | 39,553,860 |
| 24-04-25 | 3.73 | +0.54% | 28,350,520 |
| 24-04-24 | 3.71 | +0.54% | 16,298,840 |
| 24-04-23 | 3.69 | -0.27% | 18,591,600 |
| 24-04-22 | 3.7 | +0.27% | 19,262,000 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.69
CNY
Average target price
4
CNY
Spread / Average Target
+8.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.97% | 1.53B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| +0.09% | 1.65B | |
| -7.89% | 1.68B | |
| +33.40% | 1.38B | |
| +34.29% | 1.3B |
- Stock Market
- Equities
- 300026 Stock
